| abstract |
The invention relates to a pharmaceutical composition for nasal administration, based on desmopressin, which is comprised of 0.1 ... 2 mg / ml of active compound selected from 1- (3-mercaptopropionic acid) -8-D-arginine vasopressin, 1- (3-mercaptopropionic acid) -8-D-arginine vasopressin acetate or another pharmacologically acceptable, 1- or 3- (3-mercaptopropionic) -8-D-arginine vasopressin salt with or without addition of osmotic pressure regulators, buffering agents, preservatives, absorption accelerators, and an aqueous solution in volume of 5 to 75 microlitres. |